Clinical trials: Alcoholic Liver Disease
Non-Alcoholic Fatty Liver Disease, Obesity
Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study
Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease.
- Trial name
- NCT03339245
- Testing
- Fructose Solution (75 Grams), Glucose Solution (75 grams)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Alcoholic Hepatitis
Complex Exploratory Study of Alcohol-Associated Hepatitis
Alcohol-associated hepatitis is a clinical syndrome distinct from steatohepatitis or liver cirrhosis. It is associated with high mortality and characterized by an absence of effective treatment, while corticosteroids, which are…
- Trial name
- CESAH (NCT06358196)
- Where
- Slovakia
- Volunteers
- 100 people
- Sponsor
- Pavol Jozef Safarik University
Obesity, Type2diabetes
The Effects of Glucagon on Hepatic Metabolism
Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important…
- Conditions
- Obesity, Type2diabetes, NAFLD
- Trial name
- NCT05500586
- Testing
- Glucagon response study
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b Study in NASH to Assess IVA337
Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes mellitus, or insulin resistance and is very common.
- Trial name
- NATIVE (NCT03008070)
- Testing
- IVA337
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 247 people
- Sponsor
- Inventiva Pharma
Non-Alcoholic Fatty Liver
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an…
- Trial name
- NCT03953456
- Testing
- elafibranor 120mg
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Genfit
Acute-On-Chronic Liver Failure, Alcoholic Hepatitis
A-TANGO Phase 2 Study
The purpose of this research is to know if a new combination of drugs (TAK-242 and G-CSF) in combination with standard therapy for acute-on-chronic liver failure (ACLF) is more effective than standard therapy for ACLF treatment…
- Conditions
- Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic
- Trial name
- A-TANGO (NCT06890039)
- Testing
- TAK-242, G-CSF (Filgrastim)
- Where
- United Kingdom
- Volunteers
- 78 people
- Sponsor
- Yaqrit Ltd
Non-alcoholic Fatty Liver Disease
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated.
- Trial name
- SKYLINE (NCT06104319)
- Testing
- GSK4532990
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Metabolic Syndrome X
Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease
The purpose of this study is the evaluation of the effects in obese patients with metabolic syndrome on the composition of the intestinal microbiota, markers of the syndrome (hypertension, dyslipidemia, inflammation biomarkers…
- Trial name
- PROSIR (NCT02972567)
- Testing
- Lactobacillus spp, Control
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Biosearch S.A.
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.
- Trial name
- PROXYMO-ADV (NCT05364931)
- Testing
- Cotadutide
- Where
- 115 sites in United States, Argentina and 18 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease )
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth…
- Conditions
- NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis
- Trial name
- COMET cohort (NCT07241195)
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Liver Fibrosis, Alcohol Abuse
Efficacy of Simvastatin in Alcoholic Liver Fibrosis
Evaluate the efficacy of simvastatin in reducing liver fibrosis in patients with advanced fibrosis due to alcohol
- Trial name
- SIMFIB (NCT04971577)
- Testing
- Simvastatin 40mg
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Anna Cruceta
Alcohol Use Disorder, Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant…
- Trial name
- NCT03845205
- Testing
- Integrated AUD Treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Childhood Obesity, NAFLD (Non-alcoholic Fatty Liver Disease)
Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight
Definition: the overall objective is to examine childhood obesity with focus on NAFLD and its treatment. Further, we aimed to investigate the impact of genetic variation on obesity.
- Conditions
- Childhood Obesity, NAFLD (Non-alcoholic Fatty Liver Disease), Hypertension, Hyperlipidemia
- Trial name
- NCT00823277
- Testing
- Chronic care multidisciplinary intervention of childhood obesity
- Where
- Denmark
- Volunteers
- 517 people, healthy volunteers welcome
- Sponsor
- Holbaek Sygehus
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage, but will not receive study…
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05560607
- Testing
- AZD7503 Intervention
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Non-alcoholic Fatty Liver Disease, Obesity
Magnetic Resonance Imaging (MRI) Fat Quantification of the Liver
Fatty liver in the obese is a common finding; some cases develop steato-hepatosis which in the long-term can lead to liver cirrhosis.
- Trial name
- NCT02682173
- Testing
- MR Abdomen
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University Hospital, Basel, Switzerland
Non-alcoholic Steatohepatitis, Increased Iron Storage / Disturbed Distribution
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis
This is a Phase I/II open-label uncontrolled, prospective study to assess the clinical and biological effects of Deferasirox (ICL 670, Exjade®) in patients with NASH and increased iron storage / distribution of iron on liver…
- Trial name
- DEFINE (NCT01278056)
- Testing
- Exjade
- Where
- 9 sites in Germany
- Volunteers
- 5 people
- Sponsor
- Crolll Gmbh
Hepatitis, Alcoholic
Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis
To determine the efficacy and safety S-adenosyl-l-methionine in alcoholic hepatitis with cholestasis.
- Trial name
- NCT02024295
- Testing
- Ademethionine, Polyene Phosphatidyl choline
- Where
- 2 sites in China
- Volunteers
- 118 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Liver Diseases, Alcoholic, Alcohol-Related Disorders
Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
The purpose of this study is to develop a clinical understanding of early liver transplantation (ELT) for patients with severe alcoholic hepatitis (SAH) and identify the public's opinion regarding this practice.
- Conditions
- Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection
- Trial name
- NCT04234139
- Testing
- liver transplant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Johns Hopkins University
Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
Longitudinal Observational Study Of Chinese With NAFLD/NASH
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Trial name
- NCT03151473
- Where
- Hong Kong
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Humanity and Health Research Centre
Type2 Diabetes, NAFLD
Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD
One of the potential ideal strategy for NAFLD treatment may be manipulation with gut microbiota. Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.
- Conditions
- Type2 Diabetes, NAFLD, Probiotic, Omega-3 Fatty Acids
- Trial name
- NCT03528707
- Testing
- Symbiter-Omega
- Volunteers
- 48 people
- Sponsor
- Bogomolets National Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.